SynthesisEndocrine2026

Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.

Mainak Banerjee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.